The preclinical development of bicalutamide: Pharmacodynamics and mechanism of action

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 13-25

  Furr, B J A ^a   Tucker, H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FINASTERIDE; FLUOXYMESTERONE; FLUTAMIDE; GONADORELIN; GOSERELIN; HYDROXYFLUTAMIDE; LUTEINIZING HORMONE; METRIBOLONE; NILUTAMIDE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; ZANOTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CANCER CELL CULTURE; CASTRATION; CONFERENCE PAPER; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; VISUAL DISORDER;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; DOGS; MACACA NEMESTRINA; MALE; PROSTATIC NEOPLASMS; RATS;

EID: 0029561444     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80003-3     Document Type: Article

References (21)

1. Boring CC, Squires TS, and Tong T: Cancer Statistics 1992. CA Cancer J Clin 42: 19-38 [Erratum CA Cancer J Clin 1992 42: 127-128, 1992.
2. Hunter J: Observations on the glands situated between the rectum and bladder called vesiculae seminales, in Observations on Certain Parts of the Animal Oeconomy. London, 1786, p 27-44.
3. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii: 104-107, 1896.
4. Huggins C, Stevens RE, and Hodges CV: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223, 1941.
5. Veterans Administration Co-operative Urological Group. Treatment and survival of patients with cancer of the prostate. Surg Gynaecol Obstet 124: 1011-1017, 1967.
6. Furr BJA, and Milsted RAV: LH-RH analogues in cancer treatment, in Stoll B (Ed): Endocrine Management of Cancer: 2. Contemporary Therapy. Basel, Karger, 1988, pp 16-29.
7. Debruyne FMJ, Moral PF, and Geboers ADH: LHRH analogue therapy for metastatic prostate cancer. Prog Clin Biol Res 260: 27-39, 1988.
8. Bracci U, and Di Silverio F: Role of cyproterone acetate in urology, in Martini L, and Motta M (Eds): Androgens and Antiandrogens. New York, Raven Press, 1977, pp 333-339.
9. Labrie F, Dupont A, and Belanger A: Complete androgen blockade for the treatment of prostate cancer, in Vita VT De, Hellman S, Rosenberg SA (Eds): Important Advances in Oncology. Philadelphia, Lippincott, 1985, pp 193-200.
10. Snyder BW, Winneker RC, and Batzold FH: Endocrine profile of Win 49,596 in the rat: a novel androgen receptor antagonist. J Ster Biochem. 33: 1127-1132, 1989.
11. Juniewicz RE, McCarthy M, Lemp BM, Barbolt TA, Shaw C, Hollenbaugh DM, Winneker RC, Reel, JR, and Batzold FH: The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs. Endocrinology 126: 2625-2634, 1990.
12. Winneker RC, Wagner MM, and Batzold FH: Studies on the mechanism of action of Win 49,596: a steroidal androgen receptor antagonist. J Ster Biochem 33: 1133-1138, 1989.
13. Neumann F, and Jacobi GH: Antiandrogens in tumor therapy. Clin Oncol 1: 41-65, 1982.
14. Paisey RB, Kadow C, Bolton C, Hartog M, and Gingell JC: Effects of cyproterone acetate and a long acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 79: 210-211, 1986.
15. Seed M, Godsland IF, Wynn V, et al: The effects of cyproterone acetate and ethinyl estradiol on carbohydrate metabolism. Clin Endocrinol 21: 689-699, 1984.
16. Harris AL, and Cantwell BMJ: Side effects of endocrine therapies used to treat breast and prostate cancer. Clin Oncol 4: 511-533, 1985.
17. Neumann F: Pharmacology and clinical uses of cyproterone acetate, in Furr BJA, and Wakeling AE (Eds): Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action. Eastbourne, UK, Balliere & Tindall, 1987, pp 132-159.
18. Barradell LB, and Faulds D: Cyproterone: a review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 5: 1, 59-80, 1994.
19. Rabe T, Feldmann K, Grunwald K, and Runnebaum B: Liver tumours in women on oral contraceptives. Lancet 334: 1568-1569, 1994.
20. Hepatic reactions with cyproterone acetate (Cyprostat, Androcur). Curr Probl Pharmacovigil 21: 1, 1995.
21. Neri RO, Monahan MD, Meyer JG, Afonso BA and Tabachnik IA: Biological studies on an antiandrogen (SH 714), European Journal of Pharmacology, 1, 438-444, 1967.